阿维鲁单抗在治疗尿路上皮癌方面优于支持性治疗。
Avelumab Outduels Supportive Care for Urothelial Cancer.
出版信息
Cancer Discov. 2020 Jul;10(7):OF4. doi: 10.1158/2159-8290.CD-NB2020-049. Epub 2020 May 29.
Abstract
Maintenance immunotherapy following chemotherapy may improve survival in advanced urothelial cancer. In the phase III JAVELIN Bladder 100 trial, patients treated with the PD-L1 inhibitor avelumab plus best supportive care after first-line chemotherapy had significantly longer overall survival and progression-free survival than those who received best supportive care alone.
摘要
化疗后的维持免疫疗法可能会改善晚期尿路上皮癌患者的生存率。在III期JAVELIN Bladder 100试验中，接受PD-L1抑制剂阿维鲁单抗联合一线化疗后最佳支持治疗的患者，其总生存期和无进展生存期显著长于仅接受最佳支持治疗的患者。
Zotero 插件